Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07722494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jul 20, 2026 to Jul 31, 2026 · Site details revised at 2 of 2 sites · Eligibility criteria expanded, about 4 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Jul 20, 2026 to Jul 31, 2026
    • Site details revised at 2 of 2 sites
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
Trial Details
NCT Number NCT07722494
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Colorectal Cancer
Enrollment 550 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov